Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Hamed Shahbazi
AddedMar 31, 2024
UpdatedMay 1, 2026
Hamed Shahbazi

Hamed Shahbazi

Board Member, CRH Medical

Hamed Shahbazi's Career

CRH Medical
CRH Medical

Vancouver, British Columbia, CA

Board Member· Board
ChromaDex
ChromaDex

Los Angeles, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Hamed Shahbazi's Career

CRH Medical
CRH Medical
Acquired$138.9k02001Vancouver, British Columbia, CA
Board Member· Board

Leadership at CRH Medical

Eva FongEva FongBoard Member
Karimah Es SabarKarimah Es SabarBoard Member
Marc G MorinMarc G MorinBoard Member
Tushar RamaniTushar RamaniCEO

Similar to CRH Medical

Creo MedicalCreo MedicalChepstow, Gwent, GBMedical Devicesest. 2003Creo MedicalChepstow, Gwent, GB · est. 2003

UK-based Creo, founded in 2003, innovatively develops and commercialises medical devices.

Public · $90.3M77
Digital Medical TechDigital Medical TechLos Angeles, CA, USDevice Trackingest. 2016Digital Medical TechLos Angeles, CA, US · est. 2016

Digital Medical Tech: Streamlining healthcare with proactive, Bluetooth-enabled medical device tracking.

Seed · $1.5M3
Icon MedicalIcon MedicalAtlanta, GA, USMedical Devicesest. 2005Icon MedicalAtlanta, GA, US · est. 2005

Icon Medical: A leading sports medicine rep firm, innovating tools for therapists and trainers.

Series C · $27.7M7
Compact MedicalCompact MedicalIndianapolis, IN, USMedical Devicesest. 2016Compact MedicalIndianapolis, IN, US · est. 2016

Compact Medical Solutions develops bag-valve-masks for emergency breathing assistance.

Pre-Seed · $3M7
ChromaDex
ChromaDex
Public$85.1M1131999Los Angeles, CA, US
Board Member· Board

Leadership at ChromaDex

Stephen BlockStephen BlockBoard Member
Robert FriedRobert FriedBoard Member
Frank L. JakschFrank L. JakschBoard Member
Steve RubinSteve RubinBoard Member

Similar to ChromaDex

NovosNovosNew York City, NY, USNutraceuticals, Supplementsest. 2018NovosNew York City, NY, US · est. 2018

NOVOS, a science-driven supplement company, collaborates with global experts to create longevity nutraceuticals, focusing on slowing aging.

Angel · $3.1M30
BodyBioBodyBioMillville, NJ, USSupplementsest. 1999BodyBioMillville, NJ, US · est. 1999

BodyBio: A leading nutritional supplement company dedicated to advancing cellular health.

Seed · $675k34
Chroma MedicineChroma MedicineCambridge, MA, USGenomic Medicinesest. 2021Chroma MedicineCambridge, MA, US · est. 2021

Chroma Medicine: Pioneering genomic medicines to revolutionize treatment of genetic diseases.

Series B · $260M137
AgeX TherapeuticsAgeX TherapeuticsAlameda, CA, USBiotechest. 2017AgeX TherapeuticsAlameda, CA, US · est. 2017

AgeX Therapeutics, a US biotech firm, innovates in cell immortality and regenerative biology to treat aging and related diseases.

Public · $99.8M5

Hamed Shahbazi's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Hamed Shahbazi

Abdul Ahad HayeeAbdul Ahad HayeeCEO · WellHealthSeung-Il HanSeung-Il HanBoard Member · SU HoldingsGary LovemanGary LovemanBoard Member · WellRaj SharmaRaj SharmaCo-Founder · 3CLogicHosain RahmanHosain RahmanCEO · JawboneVenkat SharmaVenkat SharmaBoard Member · Advantum Health